APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN

The choice of anticoagulant therapy in patients with atrial fibrillation (AF) and concomitant diseases – coronary heart disease (CHD), including acute coronary syndrome (ACS) in history, peripheral arterial disease (PAD), is discussed in the article. The overall mortality and incidence of myocardial infarction in patients with CHD and AF is higher than in patients with AF without CHD. Patients with AF and PAD compared to patients with AF without PAD have higher risks both stroke and systemic embolism. The prescription of triple antithrombotic therapy is necessary for patients with a combination of AF and CHD who underwent percutaneous coronary interventions (in ACS or elective surgery). The possibility of prescription and duration, the choice of specific drugs and their doses should be determined individually, based on the risks of ischemic events associated with stenting, the risk of ischemic stroke and bleeding. Use of new oral anticoagulants (NOAC) instead of vitamin K antagonists (eg, warfarin), low doses of NOAC, studied in trials and proven efficacy in the prevention of stroke/systemic embolism, the use of clopidogrel as a drug of choice from the P2Y12 inhibitor group, the use of low doses of acetylsalicylic acid (ASA), the routine administration of drugs from the proton pump inhibitor group is recommended to minimize the risk of bleeding. The data of subanalysis of the ARISTOTEL randomized clinical trial, indicating a high profile of efficacy and safety of apixaban in patients with AF, depending on the presence of CHD, PAD, concomitant use of ASA, are also presented in the article. The benefits of apixaban over warfarin for reducing the risk of stroke/systemic embolism, total mortality and the risk of bleeding in a subgroup of CHD patients are just as obvious as in the general population of the ARISTOTLE study, and in the subgroup of patients without CHD. Treatment with apixaban, both in the subgroup of patients taking ASA, and a subgroup of patients without ASA, is accompanied by a lower risk of strokes and systemic embolism and a lower incidence of major bleeding. The risk of stroke or systemic embolism was similar in patients with AF and PAD randomized to the apixaban group or to the warfarin group, as well as in patients with AF without PAD. Patients with AF and PAD who received apixaban or warfarin had a similar incidence of major bleeding or clinically significant minor bleeding.

atrial fibrillation, coronary artery disease, peripheral artery disease, direct oral anticoagulant, apixaban

1. Stewart S., Hart C.L., Hole D.J., McMurray J.J. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001;86:516-21. doi: 10.1136/heart.86.5.516.

2. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-5. doi:10.1001/jama.285.18.2370.

3. Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25. doi: 10.1161/CIRCULATIONAHA.105.595140

4. Heeringa J., van der Kuip D.A., Hofman A., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949-53. doi: 10.1093/eurheartj/ehi825.

5. Naccarelli G.V., Varker H., Lin J., Schulman K.L. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534-9. doi: 10.1016/j.amjcard.2009.07.022.

6. Lloyd‐Jones D.M., Wang T.J., Leip E.P., et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042-6. doi: 10.1161/01.CIR.0000140263.20897.42

7. Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. doi: 10.1093/ejcts /ezw313.

8. Lip G.Y., Tse H.F., Lane D.A. Atrial fibrillation. Lancet. 2012;379:648-61. doi: 10.1016/S0140- 6736(11)61514-6.

9. Ringborg A., Nieuwlaat R., Lindgren P., et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace. 2008;10:403-11. doi: 10.1093/europace/eun048.

10. Wolowacz S.E., Samuel M., Brennan V.K., et al. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace. 2011;13:1375-85. doi: 10.1093/europace/eur194.

11. Rubanenko O.A. Comorbid pathology in patients with atrial fibrillation. Izvestiya Samarskogo Nauchnogo Centra Rossijskoj Akademii Nauk. 2015;17(2):367-70. (In Russ.) [Рубаненко О.А. Коморбидная патология у пациентов с фибрилляцией предсердий. Известия Самарского Научного Центра Российской Академии Наук. 2015;17(2):367-70].

12. Ballyuzek M.F., Aleksandrova L. N. Frequency and features of the course of ischemic heart disease associated with the development of atrial fibrillation. Vestnik Sankt-Peterburgskogo Universiteta. 2012;11(2):3-9. (In Russ.) [Баллюзек М.Ф., Александрова Л. Н. Частота и особенности течения ишемической болезни сердца, ассоциированной с развитием фибрилляции предсердий. Вестник Санкт-Петербургского Университета. 2012; 11(2):3-9].

13. Lip G.Y., Laroche C., Dan G.A., et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2014;16(3):308-19. doi: 10.1093/europace/eut373.

14. Dorian P., Guerra P.G., Kerr C.R., et al. Validation of a new simple scale to measure symptoms inatrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale. Circ Arrhythm Electrophysiol. 2009; 2: 218-224.doi: 10.1161/CIRCEP.108.812347.

15. Cho J.R., Angiolillo D.J. Percutaneous coronary intervention and atrial fibrillation: The triple therapy dilemma. J Thromb Thrombolysis. 2015;39:203-8. doi: 10.1007/s11239-014-1132-z)

16. Valgimigli M., Bueno H., Byrne R.A., et al.; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-60. doi: 10.1093/eurheartj/ehx419.

17. Lip G., Windecker S., Huber K., et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS) Eur Heart J. 2014; 35(45):3155-79. doi: 10.1093/eurheartj/ehu298.

18. Heidbuchel H., Verhamme P., Alings M., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467-507. doi: 10.1093/europace/euv309.

19. Napalkov D.A., Sokolova A.A., Rodionov A.V. Atrial fibrillation and ischemic heart disease: how to combine antiplatelet and anticoagulant therapy, depending on the clinical situation? Rational Pharmacotherapy in Cardiology. 2016;12(21):191-5. (In Russ.) [Напалков Д.А., Соколова А.А., Родионов А.В. Фибрилляция предсердий и ишемическая болезнь сердца: как сочетать антиагрегантную и антикоагулянтную терапию в зависимости от клинической ситуации? Рациональная Фармакотерапия в Кардиологии. 2016;12(2):191-5]. doi: 10.20996/1819- 6446-2016-12-2-191-195.

20. Connolly S.J., Ezekowitz M.D., Yusuf S., et al..; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. doi: 10.1056/NEJMoa0905561.

21. Patel M.R., Mahaffey K.W., Garg J., et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med. 2011;365(10):883-91. doi: 10.1056/NEJMoa1009638.

22. Granger C. B., Alexander J. H., McMurray J. J., et al.; ARISTOTLE Committees and Investigators.Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi: 10.1056/NEJMoa1107039.

23. Napalkov D.A., Sokolova A.A. Algorithm for individual selection of a new oral anticoagulant in patients with non-valvular atrial fibrillation based on the available evidence base.EHffektivnayafarmakoterapiya. Kardiologiya I Angiologiya. 2015;2:25-30. (In Russ.) [Напалков Д.А., Соколова А.А. Алгоритм индивидуального выбора нового перорального антикоагулянта у пациентов с неклапанной фибрилляцией предсердий на основе имеющейся доказательной базы. Эффективная фармакотерапия. Кардиология и Ангиология. 2015;2:25-30].

24. Bahit M. C., Lopes R. D., Wojdyla D. M et al. Apixabanin patients with atrial fibrillation and prior coronary artery disease:insights from the ARISTOTLE trial. Int J Cardiol. 2013;170(2):215-20. doi: 10.1016/j.ijcard.2013.10.062.

25. Rao M.P., Pokorney S.D., Granger C.B. Atrial fibrillation: a review of recent studies with the focus on thosefrom the duke clinical research institute. Scientifica (Cairo). 2014;2014:901586. doi: 10.1155/2014/901586.

26. Alexander J. H., Lopes R. D., Thomas L., et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation:insights from the ARISTOTLE trial. Eur Heart J. 2014;35(4):224-32. doi: 10.1093/eurheartj/eht445.

27. Chugh S.S., Havmoeller R., Narayanan K., et al. Worldwide epidemiology of atrial fibrillation:a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-47. doi: 10.1161/CIRCULATIONAHA.113.005119.

28. Fowkes F.G., Rudan D., Rudan I., et al. Comparison of globalestimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329-40. doi: 10.1016/S0140-6736(13)61249-0.

29. Gage B.F., van Walraven C., Pearce L., et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110:2287-92. doi:10.1161/01.CIR.0000145172.55640.93.

30. Goto S, Bhatt DL, Röther J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008;156:855-863.DOI: https://doi.org/10.1016/j.ahj.2009.03.002

31. Winkel T.A., Hoeks S.E., Schouten O., et al. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the reduction of atherothrombosis for continued health (REACH) registry. Eur J Vasc Endovasc Surg. 2010;40:9-16. doi:10.1016/j.ejvs.2010.03.003.

32. Hu P.T., Lopes R.D., Stevens S.R., et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.J Am Heart Assoc. 2017;6(1):pii:e004699. doi: 10.1161/JAHA.116.004699.

33. Pol T., Held C., Westerbergh J., Lindbäck J., et al. Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. J Am Heart Assoc. 2018;7(3):pii:e007444. doi: 10.1161/JAHA.117.007444.